Contrive Datum Insights has published "Digital Biology Market Size, Share & Industry Analysis, By Component (Software and Platforms, Services, Hardware and Instruments, Data and Content), Application (Drug Discovery, Synthetic Biology, Precision Medicine, Clinical Diagnostics, Agricultural Biotechnology, Industrial Biotechnology), Technology (Artificial Intelligence and Machine Learning, Computational Biology and Bioinformatics, Multi-Omics Analytics, Digital Twins and Biosimulation, Lab Automation and Robotics, Cloud and High-Performance Computing), End user (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Healthcare Providers, Contract Research Organizations, Agricultural Companies), Deployment mode (Cloud-Based, On-Premises, Hybrid), Biological data type (Genomic Data, Proteomic Data, Transcriptomic Data, Metabolomic Data, Imaging and Phenotypic Data, Clinical and Real-World Data), Therapeutic area (Oncology, Neurology, Infectious Diseases, Immunology and Inflammation, Rare and Genetic Diseases, Metabolic and Cardiovascular Diseases), Therapeutic modality (Small Molecules, Biologics and Antibodies, Cell and Gene Therapies, Nucleic Acid Therapeutics, Vaccines), Business model (Software Licensing and Subscription, Platform-as-a-Service, Fee-for-Service and Contract Research, Collaboration and Milestone-Based, Data Licensing), and Regional Forecast, 2026-2034". The study sizes the global digital biology market at USD 12 billion in 2025 and projects growth from USD 14 billion in 2026 to USD 44.8 billion by 2034, a compound annual growth rate of 15.65% across the forecast period.
Digital biology covers the software, data, instruments and services that apply computation to biological research and development, including machine learning, simulation, bioinformatics and automated laboratory systems. It takes the form of licensed and cloud-delivered platforms, hardware used to generate and process biological data, licensed datasets and contract analysis services. Buyers include pharmaceutical and biotechnology developers, academic institutes, healthcare providers, contract research organizations and agricultural and industrial biotechnology firms.
Adoption of AI-driven drug discovery
Adoption of AI-driven drug discovery is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 15.65% a year, the component lines exposed to it move fastest: Software and Platforms compounds at 16.94%, taking its share of revenue from 38% to 42% and its value from USD 4.56 billion to USD 18.82 billion.
On the upside, the study's bull case assumes faster uptake of AI-designed candidates in clinical pipelines, wider regulatory acceptance of simulated evidence and falling compute costs extend platform adoption beyond large pharmaceutical buyers, which would take 2034 revenue to USD 51 billion against the USD 44.8 billion base case.
The downside is specific. Biotech funding stays tight, validation of model outputs lags and data privacy rules limit data sharing, so buyers delay platform spending and consolidate vendors, and 2034 revenue lands at USD 34.5 billion. Services is the drag, 30% of the 2025 base compounding at 14.75% while the market runs at 15.65%.
Software and Platforms Leads on Both Scale and Growth
The component axis divides the field, and one line dominates both halves of it. Software and Platforms is the largest at 38% of 2025 revenue, worth USD 4.56 billion, and also the fastest at 16.94%, ending 2034 at 42%. Incumbency and momentum are not split between rivals here, leaving the position hard to attack.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Component | Software and Platforms | 38% · USD 4.56 billion | — |
| Application | Drug Discovery | 36% · USD 4.32 billion | Synthetic Biology 20.34% |
| Technology | Artificial Intelligence and Machine Learning | 24% · USD 2.88 billion | Digital Twins and Biosimulation 21.11% |
| End user | Pharmaceutical Companies | 34% · USD 4.08 billion | Contract Research Organizations 19.18% |
| Deployment mode | Cloud-Based | 52% · USD 6.24 billion | Hybrid 18.67% |
| Biological data type | Genomic Data | 32% · USD 3.84 billion | Imaging and Phenotypic Data 18.67% |
| Therapeutic area | Oncology | 34% · USD 4.08 billion | Neurology 17.5% |
| Therapeutic modality | Small Molecules | 36% · USD 4.32 billion | Cell and Gene Therapies 21.97% |
| Business model | Software Licensing and Subscription | 30% · USD 3.6 billion | Platform-as-a-Service 19.52% |
- Based on regional analysis, North America led the global digital biology market in 2025 with 42% of global revenue at USD 5.04 billion, reaching USD 16.39 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 25.5% in 2025 to 31.8% in 2034, with revenue growing from USD 3.06 billion to USD 14.25 billion.
- At 3.5% of 2025 revenue and 3.95% by 2034, Middle East and Africa is the smallest region throughout.
- Software and Platforms is projected to grow at 16.94% over the forecast period, the fastest of any component line.
- The United States is the largest single country market at USD 4.5 billion in 2025, 37.5% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across nine axes: by component, and by application, technology, end user, deployment mode, biological data type, therapeutic area, therapeutic modality and business model. The headline total carries bear, base and bull cases at USD 34.5 billion and USD 51 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.